BridgeMD
New treatment option for Adrenomyeloneuropathy Without Cerebral Involvement
Official title Epidural Spinal Cord Stimulation for Lower-limb Impairment in Adrenomyeloneuropathy
ClinicalTrials.gov ID: NCT06796920
What this study is testing
- What it's testing
- Adrenal spinal neuropathy (AMN) is a rare X-linked genetic disease caused by mutations in the ABCD1 gene, and belongs to a special type of adrenal leukodystrophy. The patient's lower limb strength is weakened, the range of motion of the ankle joint is reduced, the hip flexors are weak and affect walking, and the peripheral nerves and vibration sensation are damaged.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 22 to 50, men only
You may be able to join if
- Conforming to the diagnostic criteria of AMN, with a definite genetic testing report, and complicated by lower limb motor function disorders;
- Capable of normal communication and able to complete scale tests independently (as determined by on-site scale tests);
- Willing to participate in this study after giving informed consent;
- The muscle tone of the patient's bilateral lower extremities was elevated.
You likely can't join if
- Other inherited diseases;
- Other severe central nervous system diseases;
- History of brain surgery;
- Psychiatric and psychological diseases such as depression and anxiety;
- The presence of metallic foreign bodies or prostheses (such as cardiac pacemakers, insulin pumps) in the body, claustrophobia, and other...
- Informed consent was not obtained;
See the full eligibility criteria
- Conforming to the diagnostic criteria of AMN, with a definite genetic testing report, and complicated by lower limb motor function disorders;
- Capable of normal communication and able to complete scale tests independently (as determined by on-site scale tests);
- Willing to participate in this study after giving informed consent;
- The muscle tone of the patient's bilateral lower extremities was elevated.
- Other inherited diseases;
- Other severe central nervous system diseases;
- History of brain surgery;
- Psychiatric and psychological diseases such as depression and anxiety;
- The presence of metallic foreign bodies or prostheses (such as cardiac pacemakers, insulin pumps) in the body, claustrophobia, and other contraindications for MRI;
- Informed consent was not obtained;
- Unable to tolerate MRI-related examinations;
- Received anticoagulant, antispasmodic or antiepileptic drug therapies throughout the entire study period;
- Postoperative wound infection;
- Other motor disorders, spinal cord pathologies, fractures, osteoarthritis, amputations, scoliosis and other movement-affecting diseases.
The study team makes the final eligibility decision.
Where it's taking place
- Beijing, Beijing Municipality, China
- Chongqing, Chongqing Municipality, China
- Jingmen, Hubei, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling male, 22 years to 50 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Beijing, Beijing Municipality, China; Chongqing, Chongqing Municipality, China; Jingmen, Hubei, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.